Six-month treatment with adalimumab increased insulin sensitivity and reduced CRP and retinol-binding protein-4 (RBP-4) in a prospective study of 29 patients with moderate-to-severe psoriasis (97, 98). Here, RBP4 is linked to psoriasis.